ライフサイエンスコーパス: willingness

1 ween $5 000 and $50 000 had little impact on willingness.

2 minal withdrawal and the factors influencing willingness.

3 The intervention increased patient willingness (75%) in all groups at 1 month.

4 The willingness and ability to make particular adaptations i

5 ould be willing to participate in a biobank; willingness and attitudes did not differ between respond

6 main outcome measures were change in patient willingness and receipt of a referral to an orthopedic c

7 centered educational intervention on patient willingness and the likelihood of receiving a referral t

8 To measure the extent and willingness and to encourage and guide participants to c

9 R JMD for the more clinically relevant tasks-willingness (at least 50% of the time) to swap devices o

10 n the affected arm, then we may increase the willingness for the brain to assign force to that arm.

11 Racial difference in preference (willingness) has emerged as a key factor.

12 nal intervention significantly increased the willingness of African American patients to consider kne

13 ated a large body of evidence concerning the willingness of experimental subjects to punish uncoopera

14 and the need for HIV-positive donors and the willingness of HIV-positive recipients to accept organs

15 sm mimics ubiquitous situations in which the willingness of individuals to adopt a new product depend

16 ommunity-based interventions to increase the willingness of individuals to be a deceased organ donor.

17 ry grows; however, little is known about the willingness of patients to travel for care.

18 We determined the willingness of previous directed donors and their recipi

19 the more-affected arm, it also increased the willingness of the patients to assign force to that arm.

20 ffected side reduced noise and increased the willingness of the patients to exert effort.

21 There is forward motion and a willingness on many sides to understand and address the

22 ing women, necessarily requires a widespread willingness (particularly by those in the majority) to a

23 This willingness should be considered during design of cancer

24 We investigated their willingness to accept alternative prey and observed thei

25 What distinguished adolescents was their willingness to accept ambiguous conditions--situations i

26 Willingness to accept an IRD kidney (secondary outcome)

27 Willingness to accept an IRD kidney did not differ betwe

28 ity-of-life scores were also associated with willingness to accept high risk.

29 ception, communication, subjective norm, and willingness to accept LDKT was completed by 160 end-stag

30 MC significantly increased and the reported willingness to accept MC increased to 52.6% (255/485), 6

31 effective model for improving participants' willingness to accept MC, while Model A was most success

32 igations of the factors that affect people's willingness to accept vaccination for themselves or thei

33 ficantly (P </= .01) associated with greater willingness to adhere to treatment and greater adherence

34 asures of alliance, psychosocial well-being, willingness to adhere to treatment, and treatment adhere

35 le conceivable barriers, there was a general willingness to adopt PrEP in key populations, which sugg

36 Farmers' willingness to adopt vaccination will require vaccinatio

37 reaction severity, other medical conditions, willingness to always carry adrenaline, etc.), considera

38 smoking 10 or more cigarettes per day, and a willingness to attempt smoking cessation.

39 he impact of interventions on increasing the willingness to be a deceased organ donor (measured as co

40 associated with an increased 'hypothetical' willingness to be a living kidney donor but with marked

41 e was excellent, 97%, demonstrating fishers' willingness to be involved.

42 fessionals need to engage those men who show willingness to be involved.

43 ase is not due to an increase in the general willingness to bear risks or to altruistically help othe

44 on of methodologic quality and reduces their willingness to believe and act on trial findings, indepe

45 ific objectivity and public trust, whereas a willingness to bring implicit interests and values into

46 suggesting that male coercion and/or female willingness to cheat the partner are facilitated by male

47 by the donation) increased the participants' willingness to commit to organ donation themselves, dona

48 nication about their kidney disease, and low willingness to communicate with individuals from the soc

49 s through regular internal communication and willingness to compromise.

50 rmth, and any other cues of one's ability or willingness to confer benefits on partners.

51 rceptions of the aesthetics of FMT and their willingness to consider it as a treatment option, when p

52 y variety if caregivers focus on the child's willingness to consume a food and not just the facial ex

53 The aim of this study was to compare willingness to continue treatment with esomeprazole on-d

54 In terms of willingness to continue treatment, on-demand treatment w

55 tives that would reduce their motivation and willingness to continue.

56 utbred mice and rats, familiarity determined willingness to cooccupy the tube, with siblings and/or c

57 tween rich and poor in time, regarding their willingness to cooperate.

58 AVP increases humans' willingness to cooperate.

59 h that food deprivation increases the worm's willingness to cross the dangerous barrier by suppressin

60 Research institutions differ in their willingness to defer to a single, central institutional

61 It reduces willingness to disclose one's sexual orientation and can

62 Willingness to discuss HRQOL problems (physical, daily,

63 are variables, and current HRQOL scores with willingness to discuss HRQOL problems.

64 = 94%, P = 0.002), and had higher levels of willingness to donate (3 RCTs, 393 participants; standar

65 Information was collected on willingness to donate a kidney and the potential influen

66 ey donation-related financial burden affects willingness to donate and the experience of donation, ye

67 is study aimed to determine the magnitude of willingness to donate eyes and its associated factors, w

68 Awareness levels and willingness to donate eyes are high among the stakeholde

69 tion service is affected by various factors, willingness to donate eyes is an essential indicator of

70 The magnitude of willingness to donate eyes was moderate and positively a

71 This research assessed whether people's willingness to donate their organs for transplant purpos

72 ter (n=29,288), this study compared people's willingness to donate their organs in a representative s

73 slation, there was no difference in people's willingness to donate their organs in opt-in (58.63%) an

74 However, the effect of consent on willingness to donate was moderated by people's awarenes

75 impacts the potential donor population from willingness to donate, progression through donor assessm

76 With respondents grouped by willingness to donate, we found that 689 (68%) would don

77 ficantly associated with increased caregiver willingness to endorse palliative care and withdraw life

78 racism, sexism, welfare opposition, and even willingness to enforce group hegemony violently by parti

79 ecreasing their perceptions of injustice and willingness to engage in collective action to transform

80 ntrol is important in understanding people's willingness to engage in future-oriented behavior.

81 There is a willingness to engage in new forms of HIV prevention and

82 measures of sensation-seeking, defined as a willingness to engage in novel or intense activities.

83 t such ideation in itself does not explain a willingness to engage in punitive actions against an ene

84 on and aggression causally increases humans' willingness to engage in risky, mutually beneficial coop

85 Lastly, fixing everything else, people's willingness to engage in safe behavior waxes or wanes ov

86 e found that behaviours such as antennation, willingness to engage in trophallaxis, and mandible open

87 of expectation and/or want without which the willingness to execute adaptive behaviors is impaired.

88 prevalence of disorders showing a diminished willingness to exert effort (e.g., depression).

89 modulates incentive motivation by affecting willingness to exert effort for reward and not by reduci

90 and instrumental behavior, and a diminished willingness to exert effort is a characteristic feature

91 ic neurons underlies incentive motivation, a willingness to exert high levels of effort to obtain rei

92 a subset of negative symptoms with a reduced willingness to expend costly effort, often observed in p

93 ateral insula was negatively correlated with willingness to expend effort for rewards, consistent wit

94 omes and aversive prediction errors; reduced willingness to expend effort for rewards; and psychomoto

95 n the NAc specifically increases an animal's willingness to expend effort to obtain a goal.

96 ial prefrontal cortex were correlated with a willingness to expend greater effort for larger rewards,

97 There would be a willingness to experience inconvenience and expense at t

98 Tail handled mice showed little willingness to explore and investigate test stimuli, lea

99 turn can motivate self-sacrifice, including willingness to fight and die for the group.

100 ical diagnosis and therapy is limited by our willingness to focus directly on human health, rather th

101 cated the notion of hyperaltruism (i.e., the willingness to forego reward to spare others from harm),

102 n during planning is predictive of someone's willingness to forgo immediate small rewards in favor of

103 that developed obesity also showed increased willingness to gain access to a sucrose cue.

104 ter hunger and desire for food and a greater willingness to give up long-term monetary rewards to obt

105 humanizing language increased participants' willingness to harm strangers for money, but not partici

106 m strangers for money, but not participants' willingness to harm strangers for their immoral behavior

107 eir pain score, retrospective pain score and willingness to have a repeat procedure.

108 lly limits life expectancy or the ability or willingness to have curative lung surgery.

109 ted to critical care physicians' and nurses' willingness to help manage potential donors after circul

110 odic memory) specific events also supports a willingness to help others.

111 ative emotions, which can reduce empathy and willingness to help.

112 ntention, and not to influence a recipient's willingness to interact sexually.

113 iated the relationship between condition and willingness to interact with target.

114 Willingness to lay down one's life for a group of non-ki

115 Personal relationships and willingness to learn from each other's successes and fai

116 ned a commitment strength, w, defining their willingness to lose (in waning), gain (for increasing) o

117 Secondary outcomes included willingness to make a living kidney donation to a family

118 open mind at the system level, resulting in willingness to make changes on the basis of evidence tha

119 Chinese nurses had strong willingness to offer quality end-of-life care to patient

120 ndirect effect of intervention assignment on willingness to participate (estimated at 0.168; 95% CI,

121 oward clinical trials (P = .016) and greater willingness to participate (P = .011) at follow-up than

122 le, 188 male) were recruited on the basis of willingness to participate and being over 16 years old.

123 Attitudes toward risk, informed consent, and willingness to participate in 3 research scenarios invol

124 We assessed willingness to participate in a biobank using different

125 patients understand this agreement and their willingness to participate in additional treatment is un

126 Democratic deliberation increased willingness to participate in all scenarios, to grant le

127 d clinical trials and thereby increase their willingness to participate in clinical trials.

128 y to receiving more information, and general willingness to participate in clinical trials.

129 ral public (>/=50 years old) regarding their willingness to participate in dementia research and to g

130 one month after the session, regarding their willingness to participate in dementia research and to g

131 The general willingness to participate in health surveys is decreasi

132 mous survey: 93% (78/86) of donors indicated willingness to participate in KPD if this option had bee

133 More administrators expressed willingness to participate in the next pandemic if the r

134 There are significant discrepancies in the willingness to participate in various types of clinical

135 Willingness to participate was associated with self-iden

136 An increased willingness to participate was reported among the majori

137 sted that the benefits of psychoeducation on willingness to participate were explained by the positiv

138 nd donor travel were associated with reduced willingness to participate.

139 n criteria were age of 18 years or older and willingness to participate.

140 actors, including financial incentives, with willingness to participate.

141 teria, physician perception, and barriers in willingness to participate.

142 about the factors that may affect patients' willingness to participate.

143 and cost-effectiveness, assuming a societal willingness to pay $100000 per quality-adjusted life-yea

144 Willingness to pay (WTP) is a monetary, preference-based

145 sensitivity analysis demonstrated that, at a willingness to pay (WTP) of $50000/QALY, L was approxima

146 ability of being cost-effective at a maximum willingness to pay for a QALY of pound20 000 to pound30

147 uation approach, caregivers were asked their willingness to pay for an effective food allergy treatme

148 sing household income to increased household willingness to pay for conservation, nongovernmental org

149 ic choice experiment to show that consumers' willingness to pay for conservation-grade palm-oil produ

150 n attribute, which enabled estimation of the willingness to pay for different vaccines having differi

151 ith LAIV, however, was sensitive both to the willingness to pay for health benefits and to assumption

152 alth is about 45% and may reflect the higher willingness to pay for human health than for ecosystems

153 variable assumptions and levels of societal willingness to pay for life-years, the optimal vaccinati

154 positive drug effect (eg, high, liking, and willingness to pay for the drug).

155 Households' willingness to pay for these products was quite low on a

156 nality in noisy environments (p < .001), and willingness to pay for this attribute ranged from US$267

157 This was evident in a willingness to pay more to reduce others' pain than thei

158 h each strategy would be cost-effective at a willingness to pay of $100 000 per quality-adjusted life

159 edicted 0% chance of cost effectiveness at a willingness to pay of $100,000 per QALY gained.

160 In sensitivity analyses assuming a willingness to pay of $100,000/QALY, the annual risk of

161 Caregivers reported a willingness to pay of $20.8 billion annually ($3504 per

162 Assuming a willingness to pay of $50 000 per QALY, trabeculectomy a

163 ghest probability of cost-effectiveness at a willingness to pay of $50,000/quality-adjusted life year

164 Argus II falls below the published societal willingness to pay of EuroZone countries.

165 The results indicate that the average willingness to pay per household is CHF 100 (US$ 73) ann

166 is considered cost effective depends on the willingness to pay per patient with episodes of FN preve

167 ults were most sensitive to assuming a lower willingness to pay per quality-adjusted life-year gained

168 st effective if the decision-maker's ceiling willingness to pay reaches pound75 per error avoided at

169 were more cost-effective, mainly for higher willingness to pay threshold (US $100 000 and US $150 00

170 ed from a health system perspective, using a willingness to pay threshold equivalent to 1 month's wag

171 screening strategy was determined based on a willingness to pay threshold of $100,000 per life-year g

172 gy with the best cost-benefit ratio, up to a willingness to pay threshold of $50,000-100,000 per case

173 chance of HAP being cost-effective, given a willingness to pay threshold of Intl$16,060-equivalent t

174 n both cost and effect using a wide range of willingness to pay thresholds, we found less than 3% pro

175 We integrated results from a study of willingness to pay to reduce the burden of asthma with r

176 ntary risk-based testing under a pound20,000 willingness to pay with current treatments but likely to

177 nce of one's peers would increase consumers' willingness to pay, direct experience significantly decr

178 nt and cost per donor is less than society's willingness to pay, donor registry promotion offers posi

179 ngoro, although optimal coverage depended on willingness to pay, vaccination campaigns were always co

180 , their confidence in the results, and their willingness to prescribe the drugs.

181 71; 95% CI, 0.51 to 0.98; P=0.04), and their willingness to prescribe the hypothetical drugs (odds ra

182 t participated in Medicaid to assess whether willingness to provide appointments for new Medicaid enr

183 mong members of a French cohort according to willingness to provide part of one's 15-digit national i

184 planations critically depend on individuals' willingness to punish defectors: In models of direct pun

185 At the same time, the increased willingness to punish norm violations among similarity-f

186 (P<0.001), more concerns (P=0.01), and lower willingness to pursue live-donor kidney transplantation

187 r "never" ask patients who smoke about their willingness to quit smoking, and 249 (85%) "seldom" or "

188 f do not ask, or seldom ask, about patients' willingness to quit smoking, and most do not discuss smo

189 NHL survivors' willingness to raise HRQOL problems with their physician

190 However, no study has ever explored the willingness to receive palliative care or terminal withd

191 Willingness to recommend the HPV vaccine was moderate, w

192 ine are required to further increase nurses' willingness to recommend the vaccine and strengthen stra

193 o inequality decreases affluent individuals' willingness to redistribute.

194 There also appears to be a greater willingness to register a diagnosis of HD in patients' e

195 lications, outcomes of procedures, patients' willingness to repeat the procedure, and the amount of t

196 s or a mutation in TMEM43; and the patient's willingness to restrict exercise and to eliminate partic

197 cities with much sparser taxi fleets or when willingness to share is low.

198 ation cases in the media may affect people's willingness to sign organ donation commitment cards, don

199 Factors promoting nurses' willingness to stay included the development of meaningf

200 pation, and enforcement--affect individuals' willingness to support these international efforts.

201 esponse to the residual error, despite their willingness to sustain such an error during the training

202 sexual partner in the last 12 months, stated willingness to take an STI test, and had access to the i

203 medicine, a disciplined clinical strategy, a willingness to take calculated risks, a devoted cadre of

204 There was no difference in willingness to take PrEP between black and white MSM.

205 In multivariate analysis, willingness to take PrEP was associated with lower level

206 timating equations to explore differences in willingness to take PrEP, PrEP use, and indications for

207 follows: 1. At-risk MSM; 2. Awareness of and willingness to take PrEP; 3. Access to healthcare; 4. Re

208 dissociated from participants' impulsivity, willingness to take risks, and mood.

209 higher knowledge, fewer concerns, and higher willingness to talk to others about donation 6 weeks aft

210 loss as worse than death and showed minimal willingness to trade a reduction in this outcome with an

211 Willingness to trade years of graft survival to minimize

212 ractice as a trade-off and parents' marginal willingness to travel in minutes for practices with diff

213 Parents' marginal willingness to travel was 14 minutes (95% CI, 11-16 minu

214 association between female sex and a greater willingness to undergo bariatric surgery.

215 The weight loss expectations and willingness to undergo perioperative risk among patients

216 tistically significant differences in stated willingness to use and recommend either platform to coll

217 Therefore, this study assessed patient willingness to use non-invasive stool or blood based scr

218 en who have sex with men (MSM), we report on willingness to use PrEP and PrEP utilization.

219 Surveys of willingness to use PrEP products were administered to MS

220 METHODS AND FINDINGS: Surveys of willingness to use PrEP products were conducted with 1,7

221 ite preference for tofacitinib, and definite willingness to use tofacitinib again on the IBD PRTI at

222 Willingness to withdraw life-support was significantly l

223 error to assess their influence on surgeons' willingness to withdraw life-supporting care.

224 Changing dopamine immediately altered willingness to work and reinforced preceding action choi

225 Intra-VHPC ghrelin delivery also increased willingness to work for sucrose and increased spontaneou

226 udents were found to have 0.83 lower odds of willingness to work in a rural area (95% CI: 0.449, 1.55

227 D2R overexpression on instrumental learning, willingness to work, use of reward value representations

228 Similarly, for plastic sanitary platforms, willingness-to-pay (WTP) dropped from almost 60% at a pr

229 ategy compared with a standard strategy at a willingness-to-pay (WTP) threshold of $50 000 per QALY g

230 Results were compared by examining implied willingness-to-pay and Pearson's Rho.

231 We construct market willingness-to-pay curves and estimate future manufactur

232 to women for 5 birr ($0.29), determined with willingness-to-pay data.

233 r high-, medium-, and low-risk patients at a willingness-to-pay level of $100 000/LY.

234 ($140 per dollar invested in the trial) at a willingness-to-pay level of $100,000 per quality-adjuste

235 These ICERs are in line with willingness-to-pay levels of one times the country's gro

236 cost-effective strategy (99.9% preferred at willingness-to-pay of US$50000) and on average would sav

237 n if reduced mortality risks are valued with willingness-to-pay or as income from increased life expe

238 s our primary method and standard gamble and willingness-to-pay techniques as secondary analyses.

239 lties became the optimum strategy at the NHS willingness-to-pay threshold ( pound30,000/QALY).

240 redible interval [CrI] 104-265) is below the willingness-to-pay threshold ($599) for Tanzania.

241 n up to age 20 years remained below Norway's willingness-to-pay threshold (approximately $83 000/qual

242 One-way sensitivity analyses (willingness-to-pay threshold = $100,000/QALY) showed tha

243 At a pound30,000/QALY willingness-to-pay threshold and current prevalence, onl

244 of being cost effective at the $100,000/QALY willingness-to-pay threshold and never going below $450,

245 ts can be interpreted as cost-effective at a willingness-to-pay threshold in Belgium of euro35000 (US

246 ts can be interpreted as cost-effective at a willingness-to-pay threshold in Belgium of euro35000 (US

247 than barbiturate coma in 78% of cases if our willingness-to-pay threshold is $50,000/quality-adjusted

248 vers is excluded, (ii) 58%-84% higher if the willingness-to-pay threshold is increased to three times

249 es for 50%-69% stenosis but remained below a willingness-to-pay threshold of $100 000 per QALY for st

250 listic sensitivity analysis showed that at a willingness-to-pay threshold of $100 000 per QALY gained

251 At a willingness-to-pay threshold of $100 000 per QALY, sofos

252 At a willingness-to-pay threshold of $100 000 per QALY, the p

253 ction treatment (ICER $95 337 per QALY) at a willingness-to-pay threshold of $100 000.

254 est INMBs ($759 and $741, respectively, at a willingness-to-pay threshold of $100,000 per QALY gained

255 tus quo; >99.9% of iterations fell below the willingness-to-pay threshold of $100,000 per QALY.

256 We applied a willingness-to-pay threshold of $100,000 per quality-adj

257 lity of PP being cost-effective over SP at a willingness-to-pay threshold of $100,000/QALY.

258 tion was cost effective 76% of the time at a willingness-to-pay threshold of $100,000/QALY.

259 of $69,350, it is not cost-effective using a willingness-to-pay threshold of $100,000/quality-adjuste

260 A willingness-to-pay threshold of $100000 per QALY was use

261 t sequential therapy remained lower than the willingness-to-pay threshold of $109 000 per quality-adj

262 ectively) relative to status quo and at a US willingness-to-pay threshold of $150 000/QALY saved.

263 greater than the generally accepted societal willingness-to-pay threshold of $50 000 per QALY and thu

264 etal limit to resources was included using a willingness-to-pay threshold of $50 000 per QALY.

265 At a willingness-to-pay threshold of $50 000 per quality-adju

266 would be cost-effective (51 to 79% below the willingness-to-pay threshold of $50,000 per QALY and 76

267 ogressive keratoconus is cost effective at a willingness-to-pay threshold of 3 times the current gros

268 US$22.74 (15.49-34.45) with HPV-ADVISE, at a willingness-to-pay threshold of AUS$30 000 per quality-a

269 3,500 per week, i.e., the price generating a willingness-to-pay threshold of euro 25,000 per LYG comp

270 RI was superior to MRI alone when assuming a willingness-to-pay threshold of euro30,000.

271 reening plus surveillance exceeded the Dutch willingness-to-pay threshold of euro36 602 per life-year

272 nalysis from the societal perspective with a willingness-to-pay threshold of one times the gross dome

273 T was cost-effective in 100% of samples at a willingness-to-pay threshold of US $100 000 in the base-

274 With willingness-to-pay threshold per quality-adjusted life y

275 parents and caregivers, (iii) increasing the willingness-to-pay threshold to three times GDPpc, (iv)

276 Willingness-to-pay threshold was set at $50 000 per qual

277 ar, with 98% likelihood of meeting a $100000 willingness-to-pay threshold).

278 st-effectiveness at the pound20 000 per QALY willingness-to-pay threshold, and 70% at the pound30 000

279 cost effective in England at the current NHS willingness-to-pay threshold, and our findings informed

280 For a euro50,000 per QALY willingness-to-pay threshold, the probability of being t

281 bootstrap estimates falling under a $100,000 willingness-to-pay threshold.

282 ely to be cost-effective under a pound20,000 willingness-to-pay threshold.

283 ncremental cost-effectiveness ratio, and the willingness-to-pay threshold.Finally, the advantages and

284 treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the Unit

285 tuzumab) were more cost-effective across all willingness-to-pay thresholds in the low-risk group.

286 onged life and did so at levels below common willingness-to-pay thresholds per QALY, regardless of wh

287 cceptability curves were plotted for various willingness-to-pay thresholds to address uncertainty.

288 On the basis of commonly accepted willingness-to-pay thresholds, BTT-VAD therapy is likely

289 d is likely to be cost-effective even at low willingness-to-pay thresholds.

290 stable over a range of screening inputs and willingness-to-pay thresholds.

291 apy is cost-effective compared with accepted willingness-to-pay thresholds.

292 deaths and is cost-effective at conventional willingness-to-pay thresholds.

293 ective, with 95% CIs far below the strictest willingness-to-pay thresholds.

294 ss than $130 ($450) per person annually at a willingness-to-pay value of $50,000/QALY ($100,000/QALY)

295 ffectiveness, imagined ease-of-insertion and willingness-to-try on visual analog scales.

296 sed to determine the factors associated with willingness towards eye donation and increased awareness

297 Willingness was also increased with an advantage to the

298 o grant leeway to their surrogates, and this willingness was either sustained or increased after demo

299 (knowledge, self-efficacy, receptivity, and willingness) were assessed via patient self-report befor

300 and data sharing models, hypothesizing that willingness would be higher under more restrictive scena